• Underlying revenue increased by 2.1% to $1,373.2 million
• Underlying EBIT improved by 76.6% to $30.2 million
• Reported loss after tax was $415.6 million, a 174.9% increase from the previous year
• No final dividend declared for FY2026
• Digital transformation and cost management initiatives underway

Healius Ltd released its FY2026 Preliminary Final Report, showcasing a 2.1% increase in underlying revenue to $1,373.2 million. The company's underlying EBIT improved by 76.6% to $30.2 million, driven by stronger underlying earnings, improved second-half Pathology margins, and disciplined cost management. Despite these improvements, the reported loss after tax was $415.6 million, a 174.9% increase from the previous year, primarily due to non-cash impairment charges and discontinued operations. Healius remains focused on restoring sustainable margin and cash flow performance through revenue quality, network optimization, and technology-enabled productivity. The company did not declare a final dividend for FY2026.

Healius remains focused on restoring sustainable margin and cash flow performance through revenue quality, network optimization, and technology-enabled productivity.